DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,815,247 B2 Govindappa Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,815,247 B2 Govindappa Et Al US00881.5247B2 (12) United States Patent (10) Patent No.: US 8,815,247 B2 Govindappa et al. (45) Date of Patent: Aug. 26, 2014 (54) TARGETED/IMMUNOMODULATORY (56) References Cited FUSION PROTEINS FOREIGN PATENT DOCUMENTS (71) Applicant: Biocon Limited, Bangalore (IN) WO WO 98.33914 8, 1998 WO WO 2009/039.409 3, 2009 (72) Inventors: Nagaraj Govindappa, Karnataka (IN); WO WO 2009/114110 9, 2009 Kedarnath Sastry, Karnataka (IN); WO WO 2011, 109789 9, 2011 Maria Melina Soares, Karnatake (IN) OTHER PUBLICATIONS (73) Assignee: Biocon Limited (IN) Birch, J. R. et al. "Antibody production.” Advanced Drug Delivery Reviews, vol. 58, Nos. 5-6, Aug. 7, 2006. Carton et al. "Codon engineering for improved antibody expression (*) Notice: Subject to any disclaimer the term of this in mammalian cells.” Protein Expression and Purification, Academic patent is extended or adjusted under 35 Press, vol. 55, No. 2, Sep. 8, 2007. U.S.C. 154(b) by 0 days. Casi, Giulio et al. "Antibody drug conjugates: Basic concepts, examples and future perspectives.” Journal of Controlled Release, vol. 161, No. 2, Jan. 10, 2012. (21) Appl. No.: 13/799,409 Kalwy, S. etal. “Toward more efficient protein expression.” Molecu lar Biotechnology, Humana Press, Inc., vol.34, No. 2, Sp. Iss. SI, Oct. 22) Filed: Mar 13, 2013 1, 2006. (22) 9 Kotsopoulou, E. et al. "Optimised mammalian expression through O O the coupling of codon adaptation with gene amplification; maximum (65) Prior Publication Data yields with minimum effort.” Journal of Biotechnology, vol. 146, No. 4, Apr. 15, 2010. US 2013/02878O2A1 Oct. 31, 2013 Ortiz-Sanchez, Elizabeth et al. "Antibody cytokine fusion proteins: applications in cancer therapy.” Expert Opinion on Biological (30) Foreign Application Priority Data Therapy, vol. 8, No. 5, May 1, 2008. Apr. 30, 2012 (IN) 1689/CHFA2012 Primary Examiner — Elly-Gerald Stoica Apr. 30, 2012 (IN) ........................... 1690 CHE/2012 (74) Attorney, Agent, or Firm – Marianne Fuierer; Moore & Van Allen, PLLC (51) Int. Cl. (57) ABSTRACT A6 IK39/00 (2006.01) The present invention relates generally to the field of gener (52) U.S. Cl. ating fusion proteins to be used in cancer therapy, and more USPC .................. 424/179.1; 424/1341; 424/185.1 specifically, to nucleotide sequences encoding the fusion pro 424/192.1; 435/69.7:435/328; 530/387.3 teins, wherein the chimeric fusion proteins comprises at least (58) Field of Classification Search one targeting moiety and at least one immunomodulatory None moiety that counteracts the immune tolerance of cancer cells. See application file for complete search history. 1 Claim, 65 Drawing Sheets U.S. Patent Aug. 26, 2014 Sheet 1 of 65 US 8,815,247 B2 Anti-HER2/neu-TGF3Ril fusion protein at LC constant region Amino acid sequence of Anti-HER2/neu heavy chain: EVOLVESGGGLVOPGGSLRLSCAASGFNIKDTYHWVROAPGK GLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLOMNSL RAEDTAVYYCSRWGGDGFYAMDYWGOGTLWTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSWWTVPSSSLGTOTYCNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMSR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEOYN STYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPEKTISKAKG QPREPOVYTLPPSREEMTKNOWSLTCLVKGFYPSDAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWOQGNVFSCS VMHEALHNHYTOKSLSLSPG Amino acid sequence of Anti-HER2/neu light chain fusion protein: DOMTOSPSSLSASVGDRVTITCRASODVNTAVAWYOOKPGKA PKLLYSASFLYSGVPSRFSGSRSGTDFTLTISSLOPEDFATYYC QQHYTTPPTFGOGTKVEKRTVAAPSVFIFPPSDEQLKSGTASW WCLLNNFYPREAKVOWKVDNALOSGNSQESVTECRDSKDSTYS LSSTLTLSKADYEKHKWYACEWTHQGLSSPVTKSFNRGECGGG GSGGGGSGGGGSTIPPHVOKSVNNDMIVTDNNGAVKFPOLCK FCDVRFSTCDNQKSCMSNCSITSICEKPOEVCVAVWRKNDENI TLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSC SSDECNDNIFSEEYNTSNPD Figure 1 U.S. Patent Aug. 26, 2014 Sheet 2 of 65 US 8,815,247 B2 Anti-EGFR1-TGFBRI fusion protein at LC constant region Amino acid sequence of Anti-EGFR1 heavy chain: OVOLKOSGPGLVOPSQSLSITCTVSGFSLTNYGVHWVROSPG KGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSL OSNDTAYYCARALTYYDYEFAYWGOGTLVTVSAASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSWTVPSSSLGTOTYICNVNHKPSNTKVDK RVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMSRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHODWLNGKEYKCKVSNKALPAPEKTISKAKGOP REPORVYTLPPSRDELTKNOWSLTCLVKGFYPSDAVEWESNGO PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWOQGNWFSCSVM HEALHNHYTOKSLSLSPG Amino acid sequence of Anti-EGFR1 light chain fusion protein: DLLTOSPVILSVSPGERVSFSCRASOSIGTNIHWYOORTNGSP RLLKYASESSGPSRFSGSGSGTDFTLSINSVESEDIADYYCOO NNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEOLKSGTASWC LLNNFYPREAKVOWKVDNALOSGNSOESVTEODSKDSTYSLS STLTLSKADYEKHKWYACEVTHOGLSSPVTKSFNRGECGGGGS GGGGSGGGGSTIPPHVOKSVNNDMVTDNNGAVKFPQLCKFC DVRFSTCDNQKSCMSNCSITSICEKPOEVCVAVWRKNDENITL ETVCHDPKLPYHDFILEDAASPKCMKEKKKPGETFFMCSCSS DECNDNIFSEEYNTSNPD Figure 2 U.S. Patent Aug. 26, 2014 Sheet 3 of 65 US 8,815,247 B2 Anti-CTLA4-TGFBRI fusion protein at LC constant region Amino acid sequence of anti-CTLA4 heavy chain: OVOLVESGGGWOPGRSLRLSCAASGFTFSSYTMHWVROAP GKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLOMN SLRAEDTAIYYCARTGWLGPFDYWGOGTLVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLOSSGLYSLSSWWTVPSSSLGTOTYCNVNHKPSNTKVDK RVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMSRTP EVTCVVVDVSHEDPEVKFNWYWDGVEVHNAKTKPREEOYNST YRVVSVLTVLHODWLNGKEYKCKVSNKALPAPEKTISKAKGOP REPOVYTLPPSRDELTKNOWSLTCLVKGFYPSDIAVEWESNGO PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWOOGNVFSCSVM HEALHNHYTOKSLSLSPG Amino acid sequence of anti-CTLA4 light chain fusion protein: EIVLTQSPGTLSLSPGERATLSCRASOSVGSSYLAWYOOKPGO APRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSPWTFGOGTKVEKRTVAAPSVFIFPPSDEOLKSGTA SWCLLNNFYPREAKVOWKVDNALOSGNSOESVTEQDSKDST YSLSSTLTLSKADYEKHKWYACEVTHQGLSSPVTKSFNRGECG GGGSGGGGSGGGGSTIPPHVORKSVNNDMIVTDNNGAVKFPQ LCKFCDVRFSTCDNQKSCMSNCSITSICEKPOEVCVAVWRKN DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM CSCSSDECNDNIFSEEYNTSNPD Figure 3 U.S. Patent Aug. 26, 2014 Sheet 4 of 65 US 8,815,247 B2 Anti-HER2/neu HC-4-1BB and LC-TGFBRI fusion protein: Amino acid sequence of heavy chain-4-1BB fusion protein: EVOLVESGGGLVOPGGSLRLSCAASGFNKOTYHWVROAPGKGLEWVA RIYPTNGYTRYADSVKGRFTISADTSKNTAYLOMNSLRAEDTAVYYCSRW GGDGFYAMDYWGOGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLYSLSSVVTVPSSSLG TOTYCNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHCRDWLNGKEYKCKVSNKALPAPEKTISKAKGOP REPOVYTLPPSREEMTKNOWSLTCLVKGFYPSDIAVEWESNGOPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWOQGNVFSCSVMHEALHNHYTORKSL SLSPGGGGGSGGGGSGGGGSACPWAVSGARASPGSAASPRL1REGPE LSp0D?AGLLDLROGMFAQLVAQNVLLIDGPLSWYSD-pGLAGVSLTG GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHELQ:PLR SAAGAAALALTVOLPPASSEARNSAFGFQGRLLHCLSAGQRLGVHLHCT tARARHAWQLTQGATVLGLFRVTipt IPAGLPSPRSE Amino acid sequence of light chain-TGFBRIl fusion protein: DOMTOSPSSLSASVGDRVTITCRASODVNTAVAWYOOKPGKAPKLLYS ASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCOOHYTTPPTFGO GTKVEKRTVAAPSVFIFPPSDECQLKSGTASWCLLNNFYPREAKVOWKV DNALOSGNSOESVTEQDSKDSTYSLSSTLTLSKADYEKHKWYACEVTHQ GLSSPVTKSFNRGECGGGGSGGGGSGGGGSTIPPHVORKSVNNDMVTD NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSTSICEKPOEVCVAVW RKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSC SSDECNDNIFSEEYNTSNPD Figure 4 U.S. Patent Aug. 26, 2014 Sheet 5 of 65 US 8,815,247 B2 Anti-EGFR1 HC-4-1BB and LC-TGF3RI fusion protein: Amino acid sequence of heavy chain-4-1BB fusion protein: QVOLKOSGPGLVOPSQSLSITCTVSGFSTNYGVHWVROSPGKGLEWL GVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLOSNDTAIYYCARA LTYYDYEFAYWGOGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCL WKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWWTVPSSSLGT OTYCNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE OYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAKGOPR EPOVYTLPPSRDELTKNOWSLTCLVKGFYPSDAVEWESNGOPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKSLS LSPGGGGGSGGGGSGGGGSACPWAVSGARASPGSAASPRLREGPEL SpoopAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDpGLAGVSLTGG LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHELQ:PLRS AAGAAALALTVDLPPASSEARNSAFGFQGRLLHELSAGQRLGVHLHETE ARARHAWQLTQGATVLGLFRVTipt IpAGLPSPRSE Amino acid sequence of light chain-TGFBRIl fusion protein: DILLTOSPVILSVSPGERVSFSCRASOSIGTNIHWYOORTNGSPRLLIKYA SESSGPSRFSGSGSGTDFTLSNSVESEDIADYYCOONNNWPTTFGAG TKLELKRTVAAPSVFIFPPSDECRLKSGTASWCLLNNFYPREAKVOWKVD NALOSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKWYACEVTHQG LSSPVTKSFNRGECGGGGSGGGGSGGGGSTIPPHVOKSVNNDMIVTDN NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPCREVCVAVWR KNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCS SDECNDNIFSEEYNTSNPD Figure 5 U.S. Patent Aug. 26, 2014 Sheet 6 of 65 US 8,815,247 B2 Anti-CTLA4 HC-4-1BB and LC-TGFBRI fusion protein: Amino acid sequence of heavy chain-4-1BB fusion protein: QVOLVESGGGVVOPGRSLRLSCAASGFTFSSYTMHWVROAPGKGLEW WTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLOMNSLRAEDTAIYYCA RTGWLGPFDYWGOGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL WKDYFPEPVTVSWNSGALTSGWHTFPAVLOSSGLYSLSSWWTVPSSSLGT QTYCNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE OYNSTYRVVSVLTVLHCRDWLNGKEYKCKVSNKALPAPEKTISKAKGOPR EPOVYTLPPSRDELTKNOWSLTCLVKGFYPSDAVEWESNGOPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWOOGNWFSCSVMHEALHNHYTOKSLS LSPGGGGGSGGGGSGGGGSACPWAVSGARASPGSAASPRLREGPEL SpoDpAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGG LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHELQpLRS AAGAAALALTVDLPPASSEARNSAFGFQGRLLHELSAGQRLGVHLHETE ARARHAWQLTQGATVLGLFRVTipt IpAGLPSPRSE Amino acid sequence of light chain-TGFBRI fusion protein: EVLTQSPGTLSLSPGERATLSCRASCRSVGSSYLAWYOOKPGGRAPRLLY GAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCOOYGSSPWTF GOGTKVEKRTVAAPSVFIFPPSDEOLKSGTASWCLLNNFYPREAKVCRW KVDNALOSGNSOESVTEQDSKDSTYSLSSTLTLSKADYEKHKWYACEVT HQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSTIPPHVORKSVNNDMIV TDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSTSCEKPOEVCVAV WRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC
Load more

Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Development of Novel Bioconjugation Strategies for Creating Cancer-Targeting Nanomaterials
    Development of novel bioconjugation strategies for creating cancer-targeting nanomaterials Andri Wardiana Bachelor of Science (Chemistry) Master of Biotechnology https://orcid.org/0000-0003-1335-1320 A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2020 Australian Institute for Bioengineering and Nanotechnology (AIBN) Abstract Nanomaterials used in therapy and in vivo imaging diagnostics have the potential to be highly specific through the use of monoclonal antibody targeting, and there are several promising antibody- targeted nanomaterial candidates being tested in clinical trials. Numerous bioconjugation approaches for the attachment of antibody and antibody fragments to the surface of nanoparticles have been investigated. The challenge is to create stable and reliable bio-nanomaterials, as the conjugation approaches are complex, require optimization, and have low conjugation efficiency. Indeed, the development of an optimal and efficient method of bioconjugation is crucial for routinely producing hybrid bio-nanomaterials suitable for therapeutic and in vivo diagnostic applications. In this study, we focused on the development of bio-nanomaterial conjugates targeting prostate cancer as a model disease. For receptor targeting, we focused on prostate specific membrane antigen (PSMA), since this transmembrane protein is over-expressed in all prostate cancer stages. As such, PSMA is an ideal target in prostate cancer diagnosis and therapy. Therefore, in this investigation, we describe an active-targeting ligand for prostate cancer diagnosis and therapy, based on the anti-PSMA J591 antibody. We have developed two novel methodologies for bioconjugation of the anti-PSMA antibody fragment to nanomaterials to create novel targeting bio-nanomaterials. Both methods were applied in novel applications and provide a simplistic and efficient way to create targeted nanomaterials for in vivo imaging and therapy.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 43, No. 10, 539-549, October 2011 One target, different effects: a comparison of distinct therapeutic antibodies against the same targets Hyunbo Shim ple, four antibodies against TNF-α have been approved by the FDA -- infliximab, adalimumab, golimumab, and Department of Life Science certolizumab pegol -- with many more in clinical and Division of Life and Pharmaceutical Sciences preclinical development. The situation is similar for Ewha Womans University HER2, CD20, EGFR, and VEGF, each having one or Seoul 120-750, Korea more approved antibodies and many more under Correspondence: Tel, 82-2-3277-4240; development. This review discusses the different bind- Fax, 82-2-3277-3760; E-mail, [email protected] ing characteristics, mechanisms of action, and bio- http://dx.doi.org/10.3858/emm.2011.43.10.063 logical and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and Accepted 2 August 2011 provides insights into the development of therapeutic Available Online 3 August 2011 antibodies. Abbreviations: ADC, antibody-drug conjugate; ADCC, antibody- dependent cellular cytotoxicity; CD20, cluster of differentiation Keywords: antibodies, monoclonal; antigens, CD20; 20; CDC, complement dependent cytotoxicity; CLL, chronic pharmacology; receptor, epidermal growth factor; re- lymphocytic leukemia; ECD, extracellular domain; EGFR, epi- ceptor, erbB-2; tumor necrosis factor-α dermal growth factor receptor; EpCAM, epithelial cell adhe- sion molecule; FcγR, Fc gamma receptor;
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Download Abstracts
    ABSTRACTS International Society for Biological Therapy of Cancer 23rd Annual Meeting Abstracts (Primary Authors are Italicized) at present little is known regarding the immunobiology of BTSCs, including their intrinsic ability to be recognized by cytolytic T lymphocytes (CTLs) based on antigen presentation and antigen ADOPTIVE TRANSFER processing, their sensitivity to CTL-mediated effector mechanisms such as perforin/granzyme lytic pathways, or their employment of potential Selective Expansion of Human T Regulatory Cell Subsets and escape mechanisms that render CTLs anergic or apoptotic. We have expanded the CD133+ cancer stem cell population from T-cell Depletion: Role of Rapamycin (Sirolimus) primary human brain tumors and have demonstrated that these cells do 1,2 2 1 Christoph Bergmann , Laura Strauss , Stephan Lang , exhibit stem cell-like properties: they (1) grow in neurosphere-like 1,2 2 1 Magis Mandapathil , Theresa L. Whiteside . Department of Otorhino- clusters; (2) self-renew in vitro to reform secondary neurospheres; 2 laryngology, University of Duisburg-Essen, Essen, Germany; Department of (3) express stem cell markers; (4) differentiate to express lineage specific Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA. markers; and (5) form tumors in nonobese diabetic-severely compro- Objective: The immunosuppressive drug rapamycin promotes the mised immunodeficient mice. We are currently evaluating the utility of expansion of regulatory T-cell subsets, CD4+CD25high Foxp3+ and T cells for BTSC elimination. Using target populations that are either interleukin (IL)-10+ Tr1 cells. The mechanisms still remain unknown. loaded with a cytomegalovirus (CMV) pp65 immunodominant peptide Here, we studied expansion, survival and apoptotic pathways of human or engineered to express CMV pp65, we show that BTSCs are killed by regulatory T cells (nTreg) and Tr1 cells in response to rapamycin.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • EP3027208T3.Pdf
    RZECZPOSPOLITA (12) TŁUMACZENIE PATENTU EUROPEJSKIEGO (19) PL (11) PL/EP 3027208 POLSKA (13) T3 (96) Data i numer zgłoszenia patentu europejskiego: (51) Int.Cl. 30.07.2014 14750331.2 A61K 39/395 (2006.01) G01N 33/50 (2006.01) (97) O udzieleniu patentu europejskiego ogłoszono: 24.06.2020 Europejski Biuletyn Patentowy 2020/26 Urząd Patentowy EP 3027208 B1 Rzeczypospolitej Polskiej (54) Tytuł wynalazku: DIAGNOZA I TERAPIA NOWOTWORU Z UDZIAŁEM NOWOTWOROWYCH KOMÓREK MACIERZYSTYCH (30) Pierwszeństwo: 31.07.2013 WO PCT/EP2013/002272 (43) Zgłoszenie ogłoszono: 08.06.2016 w Europejskim Biuletynie Patentowym nr 2016/23 (45) O złożeniu tłumaczenia patentu ogłoszono: 02.11.2020 Wiadomości Urzędu Patentowego 2020/17 (73) Uprawniony z patentu: BioNTech SE, Mainz, DE Astellas Pharma Inc., Tokyo, JP TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH, Mainz, DE (72) Twórca(y) wynalazku: UGUR SAHIN, Mainz, DE ÖZLEM TÜRECI, Mainz, DE KORDEN WALTER, Saulheim, DE MEIKE WAGNER, Mainz, DE MARIA KREUZBERG, Aachen, DE SABINE HÄCKER, Mainz, DE T3 STEFAN JACOBS, Mainz, DE (74) Pełnomocnik: rzecz. pat. Dariusz Mielcarski 3027208 KANCELARIA PATENTOWA LION & LION ul. M. Karłowicza 24/1 80-275 Gdańsk PL/EP Uwaga: W ciągu dziewięciu miesięcy od publikacji informacji o udzieleniu patentu europejskiego, każda osoba może wnieść do Europejskiego Urzędu Patentowego sprzeciw dotyczący udzielonego patentu europejskiego. Sprzeciw wnosi się w formie uzasadnionego na piśmie oświadczenia. Uważa się go za wniesiony dopiero z chwilą wniesienia opłaty za sprzeciw (Art. 99 (1) Konwencji o udzielaniu patentów europejskich). LL-20/870 EP 3 027 208 B1 Opis [0001] Konwencjonalne terapie przeciwnowotworowe próbowały głównie selektywnie wykrywać i eliminować komórki nowotworowe, które w dużej mierze szybko rosną (tj.
    [Show full text]